Theratechnologies Inc T.TH

Madrigal

[palinc2000]

Madrigal Pharma announces “positive” data from NASH trial
https://seekingalpha.com/news/3710196-madrigal-pharma-announces-positive-data-from-nash-trial

[qwerty22]

Pretty stark to see the reaction in MDGLs stock since the NGM fail. It's gone from $130 to $100 since the day of NGMs announcement. And this news doesn't seem to be doing much positive either. I'm not sure right now is the best time to make your big announcement onto the scene.  

[SPCEO1]

It was positive interim data on the side-trial, not the main one, so I don't think a big reaction to that was anticipated. Still, it shows how dead the NASH stocks are right now. It has come a long way since the day ICPT rose 500% in a single day when they announced their first positve NASH data. Unending drug failures will do that to a sector.  Even with that, TH still is getting zero

[qwerty22]

https://surfingnash.com/s2-e30-the-global-liver-institute-us-nash-action-plan-what-it-is-and-how-we-all-can-help-support-it/ This has a short insight into Becky Taub's history told by herself (it starts at about 9mins). She has a strong CV as you might expect which ends as a research group leader in Roche. Then she has the gumption to spin out of Roche with two of their assets to step up

[Wino115]

Nice insights in this. In the past I listened to some Madgrigal conferences and she was excellent. I think THTX has oncology covered with Marsolais and UQAM crew.  Externally Grinspoins team and Loomva are top notch for NASH, but it may be useful in the future, perhaps if oncology becomes a reality, to bolster their internal scientific bone fides in NASH with a splashy hire.  

[scarlet1967]

“Study highlights the potential use of non-invasive assessments to diagnose NASH and monitor individual patient response to resmetirom treatment.” Apart from their results one key point is the non-invasive diagnostics seems to be reliable.  If the agencies recognize that fact and accept non-invasive diagnosis  it will make future trials much smoother. ATM I believe phase2b and 3

[Wino115]

so this was the add-on trial with NAFLD patients only.  I think they wanted to test both non-invasive diagnostics as well as get a better read on a lot of the metabolic syndrome changes in that cohort.  Maybe as a way to think about earlier usage or just to bolster it in the NASH part of the trial (?).   In either case showing good numbers for 52 weeks on a fat buster approach is a

[scarlet1967]

Another reason for muted reaction could be for many of these well established/recognized NASH companies market has already priced in some element of success, we couldn't claim the same logics as per THTX as the market seems not to have ascribed any meaningful valuation to their Phase3 program for now, I am sure any progress in NASH or oncology would have a very positive impact on the company